Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus and Influenza Vaccines
Osivax
PR-M07-20-NI-010Jul 09, 2020
Immunotherapy
Applying the Principles of Immunotherapy to Infectious Diseases
Jeffrey Stein, Ph.D.
Cidara Therapeutics
PAP-Q2-20-CL-018Jul 01, 2020
H1N1
Seaweed Extract Reduces Flu Severity
Marinova
PR-M05-20-NI-018-1563May 12, 2020
Influenza
Bloomfield Hills Teen Awarded $25,000 for Developing Method to Create Universal Influenza Vaccine
Davidson Institute
PR-M08-19-NI-060Aug 21, 2019
Influenza
Sanofi Signs Strategic Deal for Exclusive US Over-the-Counter Rights to Tamiflu® in Flu Care
Sanofi
PR-M07-19-NI-061Jul 24, 2019
Influenza
Genentech’s Xofluza Flu Treatment Effective in Children
Emilie Branch
Pharma's Almanac
PAO-M07-19-NI-019Jul 22, 2019
Influenza
GSK Ships 2019-20 Seasonal Influenza Vaccines for US Market
Nice Insight
PR-M07-19-NI-047-2363Jul 19, 2019
Vaccines
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
Moderna
PR-M05-19-NI-041May 14, 2019
FDA Approval
Genentech Receives FDA Approval for Flu Medicine
Pharma's Almanac
PAO-M11-18-NI-001Nov 05, 2018
Influenza
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
Abbott
PR-M10-18-NI-099Oct 29, 2018
Influenza
Cell-Based Flu Vaccines Appear to Be More Effective than Egg-Based Strains
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M10-18-NI-017Oct 22, 2018
Influenza
FluMist Shipped by AstraZeneca
Nice Insight
PAO-M10-18-NI-007-3592Oct 04, 2018
Collaboration
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech
PR-M09-18-NI-052Sep 18, 2018
Vaccines
GSK Ships 2018-19 Seasonal Influenza Vaccines for US Market
GSK Contract Manufacturing
PR-M08-18-NI-110Aug 29, 2018
Influenza
Brexit Issues Could Impact Flu Shot Deliveries to the UK
Nice Insight
PAO-M08-18-NI-022Aug 22, 2018
Influenza
Anti-Flu Drug Exploits Weakness in H3N2 Strain
Emilie Branch
Pharma's Almanac
PAO-M03-18-NI-021Mar 23, 2018
Influenza
New BI Vaccine Allows Very Early Vaccination of Piglets Against Swine Flu
Nigel Walker
Nice Insight
PAO-M03-18-NI-010Mar 09, 2018
Influenza
GSK presents new efficacy data for FLUARIX® QUADRIVALENT (Influenza Vaccine) in children 6 months through 35 months of age
GSK
PR-M02-18-NI-87Feb 23, 2018
Vaccine
GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older
GlaxoSmithKline
PR-M01-18-NI-046Jan 17, 2018
Capacity Expansion
Sanofi Expanding Manufacturing Capacity for Quadrivalent Influenza Vaccine
Guy Tiene
Nice Insight
PAO-M10-17-NI-043Oct 26, 2017